Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 286

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 7
Chunk 286
---
 the segment’s operational and administrative cost structure and the impact of product mix, net of 2023 inventory write-offs - 245 basis points

2024 vs. 2023 operating profit margin comparisons were favorably impacted by:

•2023 impairment charges related to technology-based intangible assets and other assets - 75 basis points

Amortization of intangible assets as a percentage of sales increased in 2024 as compared with 2023 due to the decrease in sales and relatively consistent amortization expense year-over-year.  

LIFE SCIENCES

The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies.  Additionally, the segment provides products and consumables used to filter and remove contaminants from a variety of liquids and gases in many end-market applications. 

Life Sciences Selected Financial Data 

 Year Ended December 31($ in millions)202420232022Sales$7,329 $7,141 $7,036 Operating profit879 1,209 1,414 Depreciation 167 129 112 Amortization of intangible assets576 429 419 Operating profit as a % of sales12.0 %16.9 %20.1 %Depreciation as a % of sales2.3 %1.8 %1.6 %Amortization as a % of sales7.9 %6.0 %6.0 %

Sales Growth and Core Sales (Decline) Growth

2024 vs. 20232023 vs. 2022Total sales growth (GAAP)2.5 %1.5 %Impact of:Acquisitions(6.0)%(1.5)%Currency exchange rates 1.5 %1.0 %Core sales (decline) growth (non-GAAP)(2.0)%1.0 %

2024 Sales Compared to 2023 

Price increases in the segment contributed 1.0% to sales growth on a year-over-year basis during 2024 as compared with 2023 and are reflected as a component of core sales above. 

During 2024, total Life Sciences segment sales increased 2.